The LUNGevity Foundation has issued Requests for Applications (RFAs) for translational research for its career development, early detection, and targeted therapeutics awards.
The Career Development Awards for Transitional Research were developed to aid future leaders who have new ideas for lung cancer research. The Early Detection Awards support research projects directed at new approaches for improving clinical methods for the early detection and diagnosis of lung cancer. Targeted Therapeutics Awards support research projects directed at discovery and validation of biomarkers or novel targeted therapeutics that will make a difference in the clinical treatment and survival of patients.
Those applicants who are successful will receive $100,000 per year for a possible period of 3 years. They will also participate as non-voting members of LUNGevity’s Scientific Advisory Board for the duration of the award. Successful projects will be funded at $100,000 per investigator per year for a maximum of $600,000 over 2 years. Applicants may apply for Early Detection or Targeted Therapeutics Awards as individuals or in teams of up to 3 investigators.
The RFAs are available on LUNGevity’s Web site, as well as on the proposalCENTRAL Web site.